Salarius Pharmaceuticals (SLRX) News Today $1.43 +0.03 (+2.14%) (As of 01:00 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Salarius Pharmaceuticals (NASDAQ:SLRX) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comSLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q2 2024August 12, 2024 | investorplace.com(SLRX) - Analyzing Salarius Pharmaceuticals's Short InterestJuly 30, 2024 | benzinga.comWhy Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day SessionJuly 25, 2024 | benzinga.comWhy Is Salarius Pharmaceuticals (SLRX) Stock Up 90% Today?July 23, 2024 | investorplace.comWhy Is Salarius Pharmaceuticals (SLRX) Stock Up 90% Today?July 23, 2024 | investorplace.comSalarius Pharmaceuticals Inc.July 19, 2024 | barrons.comSalarius Pharmaceuticals (NASDAQ:SLRX) Stock, Short Interest ReportJuly 19, 2024 | benzinga.comSalarius Pharmaceuticals Announces 1-for-8 Reverse Stock SplitJune 12, 2024 | globenewswire.comSLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024May 14, 2024 | investorplace.comSLRX Pursues Important GoalApril 2, 2024 | finance.yahoo.comWall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation DataMarch 27, 2024 | msn.comWhy Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving PremarketMarch 25, 2024 | msn.comSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 23, 2024 | finanznachrichten.deSalarius: Q4 Earnings SnapshotMarch 22, 2024 | sfgate.comSalarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 22, 2024 | globenewswire.comQuoin stock craters 47% on public offering after rallying in prior sessionMarch 5, 2024 | msn.comQuoin stock soars 60% on FDA update for ichthyosis drugMarch 4, 2024 | msn.comSalarius Pharmaceuticals Implements Cost-savings MeasuresFebruary 22, 2024 | markets.businessinsider.comSalarius's CEO David Arthur steps downFebruary 22, 2024 | msn.comSalarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing ExpensesFebruary 22, 2024 | finance.yahoo.comSalarius Pharmaceuticals Inc (SLRX)February 9, 2024 | uk.investing.comSalarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein DegradersJanuary 16, 2024 | finance.yahoo.comSquare Pharmaceuticals Ltd.January 13, 2024 | wsj.comInvestigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient EnrollmentJanuary 3, 2024 | finance.yahoo.comSLRX Continues Work as it Seeks AlternativesNovember 10, 2023 | finance.yahoo.comSalarius Pharmaceuticals Inc SLRXNovember 8, 2023 | morningstar.comSalarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development ProgramNovember 7, 2023 | finance.yahoo.comSalarius Pharmaceuticals cuts half of workforce despite positive clinical developmentsAugust 10, 2023 | bizjournals.comSalarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business UpdateAugust 10, 2023 | finance.yahoo.comSLRX Pursuing Strategic AlternativesAugust 9, 2023 | finance.yahoo.comTrading was temporarily halted for "SLRX" at 04:08 PM with a stated reason of "News pending."August 8, 2023 | marketbeat.comWatching Salarius Pharma; Zacks Small-Cap Research Sets $6.75 Price TargetJuly 11, 2023 | benzinga.comSLRX Continues Cancer Fight with Phase I Trial ApprovalJuly 11, 2023 | finance.yahoo.comSalarius Pharmaceuticals Gets FDA Clearance for Lymphoma Drug ApplicationJuly 11, 2023 | marketwatch.comSalarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma PatientsJuly 11, 2023 | finance.yahoo.comSalarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid CongressJune 12, 2023 | finance.yahoo.comSalarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesMay 17, 2023 | marketwatch.comSalarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesMay 16, 2023 | finance.yahoo.comSalarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesMay 12, 2023 | finance.yahoo.comRecap: Salarius Pharmaceuticals Q1 EarningsMay 11, 2023 | msn.comSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business UpdateMay 11, 2023 | finanznachrichten.deSalarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business UpdateMay 11, 2023 | finance.yahoo.comSalarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhoodMay 9, 2023 | msn.comFDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing SarcomaMay 9, 2023 | finance.yahoo.comSalarius Pharmaceuticals, Inc. (SLRX)May 2, 2023 | uk.finance.yahoo.comSalarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164May 1, 2023 | finance.yahoo.comSalarius Pharmaceuticals (FRA:FP1) Price Target Decreased by 7.80% to 55.93April 24, 2023 | msn.comSalarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual MeetingApril 20, 2023 | finance.yahoo.comSalarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational ConferenceApril 4, 2023 | finance.yahoo.com Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention. 👉 Click here to access your FREE report now! SLRX Media Mentions By Week SLRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLRX News Sentiment▼0.000.47▲Average Medical News Sentiment SLRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLRX Articles This Week▼00▲SLRX Articles Average Week Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SNOA News Today ADXN News Today MBRX News Today GLTO News Today ATHE News Today COEP News Today SYRS News Today BCLI News Today BIOR News Today ABVC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
